Development of a high-throughput antiviral assay for screening inhibitors of Chikungunya virus and generation of drug-resistant mutations in cultured cells
Autor(es): Gong Edwin Yunhao, Bonfanti Jean-François, Ivens Tania, Van der Auwera Marijke, Van Kerckhove Barbara, Kraus Guenter
Resumo: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus that has already infected millions of people in recent large-scale epidemics in Africa, the isl-s of the Indian Ocean, South - Southeast Asia, - northern Italy. The infection is still ongoing in many countries, such as India. Although the fatal rate is approximately 0.1% in the La Réunion outbreak, it causes painful arthritis-like symptoms that can last for months or even years. Currently, neither vaccine nor approved antiviral therapy exists to protect humans from chikungunya infection. Therefore, there is an urgent unmet medical need for the development of antiviral drugs for pre-exposure prophylaxis -/or treatment of chikungunya infections. In this chapter, we describe a fully validated ATP/luminescence assay that is effective for high-throughput screening of CHIKV inhibitors. Protocols for growing CHIKV stocks - generating drug-resistant viral variants for modes of action studies of compounds are also described.
Palavras-Chave: Chikungunya virus; Antiviral; High-throughput screening; CPE inhibition; Drug resistance selection
Imprenta: Methods in Molecular Biology, v. 1030, p. 29-38, 2013
Identificador do objeto digital: 10.1007/978-1-62703-484-5_32
Descritores: Chikungunya virus - Cell ; Chikungunya virus - Pathogenesis ; Chikungunya virus - Infectious diseases ; Chikungunya virus - Viral infections ; Chikungunya Virus - Virus ; Chikungunya virus - Vaccine ; Chikungunya virus - Epidemic
Data de publicação: 2013
